Evogene Stock Earnings Reports

Evogene reported strategic progress in Q1 2026 focused on concentrating its technology and commercial efforts around its proprietary Campus AI generative engine and two target markets: small-molecule pharmaceuticals and next-generation agricultural chemicals. Key technology milestones include continued collaboration with Google to integrate advanced AI agents into Campus to extract insights from scientific literature and build proprietary datasets. Pharma activities gained momentum with three new collaborations (Systasy/Ludwig Maximilian University Hospital on neutrophil-driven inflammatory diseases; Unravel Biosciences on demyelinating disorders; and Queensland University of Technology on chemotherapy resistance), and a growing internal small-molecule pipeline. Agricultural efforts, run through subsidiary AgPlenus, saw termination of the Bayer collaboration due to an inherent target biology issue, but significant internal progress on a Septoria fungicide program—demonstrating iterative improvement using ChemPass AI from 440 initial candidates to multiple validated leads. Financially, consolidated cash was $13.1 million as of March 31, 2026; Q1 revenue fell to $0.3M (from $2.3M) largely due to lower seat sales; operating loss was ~$3.2M and net loss ~$5.9M, driven by decreased revenues and increased net financing expenses related to warrant accounting. The company also streamlined non-core subsidiaries (Lavie, Biomica, Costera) with distributions and scaled-down operations. Management expects continued progress across technology, pharma, and ag pipelines, with business development efforts ongoing to secure strategic collaborations and potential equity-containing transactions.